Dr. Murray Krahn is the Director of THETA (Toronto Health Economics and Technology Assessment Collaborative); F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto; Professor in the Faculties of Medicine and Pharmacy, University of Toronto; Senior Scientist at the Toronto General Hospital Research Institute; and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. He completed a Master's Degree in Clinical Epidemiology at McMaster University, and a Clinical Fellowship in Medical Decision Making at the New England Medical Centre in Boston. Dr. Krahn's research program focuses on the use of decision analytic methods to examine health policy and health decision-making. He leads one of the leading technology assessment institutes in the country.
My central area of research interest has been the application of decision analysis and economic evaluation to broad questions of health and clinical policy. This methodologic focus has been expressed in a variety of content areas including prostate cancer and viral hepatitis. More recent interests include evaluating the role of disease specific utility assessment, using administrative data to build longitudinal cost models, and evaluating the role of health technology assessment in pharmaceutical reimbursement decisions.
Carpal Tunnel Syndrome Management in Breast Cancer Survivors at Risk for Lymphedema: A Markov Model.
Plast Reconstr Surg. 2018 May;141(5):689e-696e
MPA, a Free, Accessible, and Efficient Pipeline for Single Nucleotide Variant Annotation and Prioritization for Next-Generation Sequencing Routine Molecular Diagnosis.
J Mol Diagn. 2018 Apr 21;:
J Am Geriatr Soc. 2018 Apr 20;:
J Wound Care. 2017 07 01;26(Sup7):S4-S13
The Bladder Utility Symptom Scale (BUSS): A Novel Patient-Reported Outcome Instrument in Bladder Cancer.
J Urol. 2018 Mar 09;:
J Neuromuscul Dis. 2018;5(1):21-28
Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology.
Pharmacoecon Open. 2017 Sep;1(3):167-173
J Womens Health (Larchmt). 2018 Jan 10;:
Diagnostic accuracy of level IV portable sleep monitors versus polysomnography for obstructive sleep apnea: a systematic review and meta-analysis.
Sleep Breath. 2018 Jan 09;:
CMAJ Open. 2018 Jan 04;6(1):E1-E10
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Director of THETA (Toronto Health Economics and Technology Assessment Collaborative)
F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto
Professor in the Faculties of Medicine and Pharmacy, University of Toronto
Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto.